Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of action
AbstractContext Jiang-Zhi-Ning (JZN), a traditional Chinese medicinal formula, is used to treat hyperlipidemia in clinics.Objective To screen the hypolipidemic “bioequivalent substance system (BSS)” of JZN and elucidate the potential hypolipidemic mechanism.Materials and methods In vitro, the TG con...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Pharmaceutical Biology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13880209.2023.2243999 |
| _version_ | 1797234857539010560 |
|---|---|
| author | Yumiao Li Yan Zhang Yu Zhang Tianfeng Lin Yanyan Gao Yuan Cai Chang Zhou Leyi Yang Bin Liu Shifen Dong Yanyan Jiang |
| author_facet | Yumiao Li Yan Zhang Yu Zhang Tianfeng Lin Yanyan Gao Yuan Cai Chang Zhou Leyi Yang Bin Liu Shifen Dong Yanyan Jiang |
| author_sort | Yumiao Li |
| collection | DOAJ |
| description | AbstractContext Jiang-Zhi-Ning (JZN), a traditional Chinese medicinal formula, is used to treat hyperlipidemia in clinics.Objective To screen the hypolipidemic “bioequivalent substance system (BSS)” of JZN and elucidate the potential hypolipidemic mechanism.Materials and methods In vitro, the TG content in HepG2 cells was determined after the intervention of the combination of advantageous components (CAC) by uniform design. In vivo, hyperlipidemia models were established by Triton WR-1339 (400 mg/kg; i.p.) in male ICR mice, and corresponding treatments were administered via oral administration once. The mice were divided into 12 groups (n = 5): control, hyperlipidemic model, simvastatin (positive control, 20 mg/kg), gradient doses of JZN granules (2, 4 and 8 g/kg) and the hypolipidemic effective extraction (HEE) of JZN (120, 240 and 480 mg/kg) and CAC groups (20, 40 and 160 mg/kg). Serum TC, TG, LDL-C and HDL-C were performed after 24 h. Transcriptomics and qRT–PCR technology were used to explore the mechanism of the “BSS” of JZN.Results In vitro, the ratio of CAC was determined. CAC could reduce the TG content in HepG2 cells (77.21%). Compared with the model group, the high dose of CAC could markedly decrease the levels of TC (61.86%), TG (105.54%) and LDL-C (39.38%) and increase the level of HDL-C (232.67%). CAC was proved to be the “BSS”. Transcriptomics and qRT–PCR analysis revealed CAC regulated non-alcoholic fatty liver disease, bile secretion, PPAR and adipocytokine signalling pathway.Discussion and conclusions These findings provided new feasible ideas and methods for the elucidation of the pharmacodynamic material basis. |
| first_indexed | 2024-03-09T00:09:31Z |
| format | Article |
| id | doaj.art-bc40131453e34cbe8f46a68fd2f98fbc |
| institution | Directory Open Access Journal |
| issn | 1388-0209 1744-5116 |
| language | English |
| last_indexed | 2024-04-24T16:38:44Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Pharmaceutical Biology |
| spelling | doaj.art-bc40131453e34cbe8f46a68fd2f98fbc2024-03-29T11:10:26ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162023-12-016111374138610.1080/13880209.2023.2243999Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of actionYumiao Li0Yan Zhang1Yu Zhang2Tianfeng Lin3Yanyan Gao4Yuan Cai5Chang Zhou6Leyi Yang7Bin Liu8Shifen Dong9Yanyan Jiang10School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, ChinaAbstractContext Jiang-Zhi-Ning (JZN), a traditional Chinese medicinal formula, is used to treat hyperlipidemia in clinics.Objective To screen the hypolipidemic “bioequivalent substance system (BSS)” of JZN and elucidate the potential hypolipidemic mechanism.Materials and methods In vitro, the TG content in HepG2 cells was determined after the intervention of the combination of advantageous components (CAC) by uniform design. In vivo, hyperlipidemia models were established by Triton WR-1339 (400 mg/kg; i.p.) in male ICR mice, and corresponding treatments were administered via oral administration once. The mice were divided into 12 groups (n = 5): control, hyperlipidemic model, simvastatin (positive control, 20 mg/kg), gradient doses of JZN granules (2, 4 and 8 g/kg) and the hypolipidemic effective extraction (HEE) of JZN (120, 240 and 480 mg/kg) and CAC groups (20, 40 and 160 mg/kg). Serum TC, TG, LDL-C and HDL-C were performed after 24 h. Transcriptomics and qRT–PCR technology were used to explore the mechanism of the “BSS” of JZN.Results In vitro, the ratio of CAC was determined. CAC could reduce the TG content in HepG2 cells (77.21%). Compared with the model group, the high dose of CAC could markedly decrease the levels of TC (61.86%), TG (105.54%) and LDL-C (39.38%) and increase the level of HDL-C (232.67%). CAC was proved to be the “BSS”. Transcriptomics and qRT–PCR analysis revealed CAC regulated non-alcoholic fatty liver disease, bile secretion, PPAR and adipocytokine signalling pathway.Discussion and conclusions These findings provided new feasible ideas and methods for the elucidation of the pharmacodynamic material basis.https://www.tandfonline.com/doi/10.1080/13880209.2023.2243999Hyperlipidemiauniform designtranscriptome sequencing |
| spellingShingle | Yumiao Li Yan Zhang Yu Zhang Tianfeng Lin Yanyan Gao Yuan Cai Chang Zhou Leyi Yang Bin Liu Shifen Dong Yanyan Jiang Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of action Pharmaceutical Biology Hyperlipidemia uniform design transcriptome sequencing |
| title | Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of action |
| title_full | Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of action |
| title_fullStr | Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of action |
| title_full_unstemmed | Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of action |
| title_short | Optimization of the proportions of advantageous components in the hypolipidemic “bioequivalent substance system” of Jiang-Zhi-Ning and its mechanism of action |
| title_sort | optimization of the proportions of advantageous components in the hypolipidemic bioequivalent substance system of jiang zhi ning and its mechanism of action |
| topic | Hyperlipidemia uniform design transcriptome sequencing |
| url | https://www.tandfonline.com/doi/10.1080/13880209.2023.2243999 |
| work_keys_str_mv | AT yumiaoli optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT yanzhang optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT yuzhang optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT tianfenglin optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT yanyangao optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT yuancai optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT changzhou optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT leyiyang optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT binliu optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT shifendong optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction AT yanyanjiang optimizationoftheproportionsofadvantageouscomponentsinthehypolipidemicbioequivalentsubstancesystemofjiangzhininganditsmechanismofaction |